Core Insights - The second quarter of 2024 showed high production levels and a significant intake of new orders, aligning with full-year expectations for revenue and operating profit, while profit after tax improved due to the winding-up of loss-making international activities [1][6]. Order Intake and Order Book - New orders won in the second quarter amounted to DKK 8.1 billion, marking a high level for a single quarter [2]. - The order portfolio was valued at DKK 23 billion, providing strong resilience against potential market fluctuations, with DKK 11.6 billion in final and awarded orders, DKK 5.8 billion in awarded but not yet contracted orders, DKK 4.9 billion in future projects under construction partnerships, and DKK 0.7 billion in joint ventures [6]. Financial Performance - Revenue for the quarter was DKK 2,675 million, slightly up from DKK 2,665 million, with Enemærke & Petersen showing growth while MT Højgaard Danmark experienced a slight decline [6]. - Operating profit (EBIT) was DKK 100 million, down from DKK 124 million, impacted by capacity-building investments and losses in joint ventures [6]. - Profit after tax improved to DKK 68 million from DKK 52 million in the previous year, attributed to lower losses from discontinued operations [6]. - Cash flows from operating activities improved from an outflow of DKK 52 million to an inflow of DKK 76 million [6]. Guidance for Future Performance - The company maintains its guidance for 2025, expecting revenue to be around DKK 10.0-10.5 billion and operating profit (EBIT) to be DKK 400-450 million [3][6]. - The outlook is supported by a high order coverage, a solid pipeline, and strong exposure to growth segments of the market [3].

Core Points - Falcon Oil & Gas Ltd. will host a presentation and Q&A session led by CEO Philip O'Quigley on 27 August 2025, following the Annual General and Special Shareholder meeting [2] - The event is accessible to all existing and potential shareholders, with questions being accepted before and during the live presentation [3] Company Overview - Falcon Oil & Gas Ltd. is an international oil and gas company focused on the exploration and development of unconventional oil and gas assets, primarily in Australia, South Africa, and Hungary [5] - The company is incorporated in British Columbia, Canada, and has its headquarters in Dublin, Ireland [5]

Financial Statements Schedule - Jyske Bank plans to release its 2025 financial results on 5 February 2026, including the annual report and risk management report [1] - The interim report for the first quarter of 2026 is scheduled for 6 May 2026 [1] - The interim report for the first half of 2026 will be released on 19 August 2026 [1] - The interim report for the first nine months of 2026 is set for 28 October 2026 [1] Annual General Meeting - Jyske Bank's Annual General Meeting is scheduled for 17 March 2026 [1] - Items for the agenda must be submitted in writing to the management by 2 February 2026 [1]

Core Insights - Jyske Bank has significantly improved customer satisfaction, being named "Best at Private Banking" for the tenth consecutive year, which is a central element of its strategy [1][6][7] - In H1 2025, earnings per share increased by 1% to DKK 39.4, despite lower short-term interest rates, with net profit expectations for 2025 set at the upper end of DKK 3.8bn-4.6bn [2][9][11] - The Danish economy is experiencing growth, with rising employment and housing market activity, although geopolitical uncertainties and tariff changes pose challenges [3] Financial Performance - Core income decreased by 5% to DKK 6,503m due to lower net interest income, while net fee and commission income rose by 14% [12] - Core expenses increased to DKK 3,195m, influenced by the relocation of premises, but underlying core expenses decreased by 1% [13] - Loan impairment charges resulted in an income of DKK 47m in H1 2025, reflecting solid credit quality, with a capital ratio of 21.5% and a common equity tier 1 capital ratio of 16.3% [14] Strategic Developments - The strategy focuses on optimizing operations, investing in customer segments, and enhancing digital platforms to support sustainable transitions and improve risk management [4] - The use of AI in daily operations has increased, allowing employees to dedicate more time to customer interactions [4] - A new Group Executive member, Ingjerd Blekeli Spiten, has been appointed as Head of Personal Banking and Wealth Management [5] Operational Changes - Jyske Bank has consolidated its Copenhagen offices into a new location, the Glass Cube at Kalvebod Brygge, promoting collaboration and accessibility [8][10]

Core Insights - Coloplast reported organic growth of 7% and an EBIT margin of 28% in Q3 2024/25, with reported revenue in DKK growing by 1% [1][4] - For the first nine months of 2024/25, organic growth remained at 7% with reported revenue increasing by 4% to DKK 20,914 million [2][4] - The company maintains its FY 2024/25 guidance for organic growth around 7% and an EBIT margin before special items of 27-28% [3][4] Financial Performance - EBIT for Q3 was DKK 1,915 million, a 2% increase from the previous year, with an EBIT margin of 28% compared to 27% last year [4] - Adjusted net profit before special items was DKK 3,778 million, a decrease of DKK 15 million from last year, with adjusted diluted EPS before special items decreasing by 1% to DKK 16.76 [4] - The reported growth in DKK is now expected to be 3-4%, with negative impacts from currency fluctuations and the Skin Care divestment [4] Business Segment Performance - Organic growth rates by business area include: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4%, and Interventional Urology 4% [4] - Advanced Wound Care experienced a decline of -2% primarily due to a product return in China, expected to negatively impact revenue by around DKK 80 million in H2 [4] - Kerecis grew by 17% with a 13% EBIT margin before PPA amortization, although growth was impacted by a slowdown in the outpatient setting [4] Strategic Developments - Changes to the Executive Leadership Team were announced to support the execution of the new company strategy towards 2030 [4][5] - The search for Coloplast's new CEO is ongoing, with a presentation of the 2030 strategy planned for the Capital Markets Day on 2 September [5]

Baltic tour operator Novaturas generated EUR 74 million in revenue in the first half of the year, according to unaudited results. Compared to H1 2024, revenue declined by 19%, mainly due to a streamlined travel program. This strategy, introduced to address last year’s market oversupply, is already delivering results: net losses decreased from EUR 2.28 million to EUR 791 thousand. The company expects to operate profitably in the second half of the year, which should improve the overall annual result. “The fi ...

Core Insights - Coloplast is restructuring its Executive Leadership Team (ELT) to align with its new strategy aimed at enhancing customer experience and innovation [1][2][3] - The new strategy emphasizes placing customers at the center of operations and aims to set industry standards while leading the market [2][3] Business Structure Changes - Coloplast has established two distinct business units: Chronic Care and Acute Care, to better address market dynamics and customer needs [4] - A new Chronic Care Commercial business unit has been created, incorporating existing sales regions and functions, including Atos Medical's Voice & Respiratory Care [5] - A stand-alone Chronic Care R&D function is being set up to accelerate product innovation and market delivery [6] Leadership Changes - Nicolai Buhl, Executive Vice President, will leave Coloplast as part of the restructuring, with Caroline Vagner Rosenstand appointed as the new Executive Vice President of Chronic Care Commercial [7][8] - Rasmus Just will assume the role of Executive Vice President of Chronic Care R&D starting November 1, bringing experience from both Coloplast and Novo Nordisk [8][9] Acute Care Unit Introduction - The Acute Care business unit will include Interventional Urology, Advanced Wound Dressings, and Kerecis, focusing on premium products used in specialized clinics and hospitals [10] - The commercial organizations of Advanced Wound Dressings and Kerecis are merging into a new Wound & Tissue Repair organization, led by Fertram Sigurjonsson [11][12] New Executive Leadership Team - The new ELT includes Lars Rasmussen as interim CEO and Anders Lonning-Skovgaard as CFO, along with other key executives overseeing various business units [15][19]

Sampo plc, stock exchange release, 19 August 2025 at 8:30 am EEST Sampo plc’s share buybacks 18 August 2025 On 18 August 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code) 7,3239.91AQEU 115,6929.90CEUX 33,9109.90TQEX 168,8049.90<td style="width:5cm ...

Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 millionTotal revenue grows significantly by 36% to CHF 104.0 millionOperating profit surges by 160% to CHF 24.0 millionOperating cash flow increases by 29% to CHF 23.1 millionFull-year 2025 guidance: on track and updated to reflect recent in-licensing of a novel oral phase 3-ready antibiotic Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 19, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage bio ...

Core Insights - Trifork Group reported a Q2 revenue growth of 5.1%, driven by strong performance in product segments and public sector engagements [1][5] - The company maintains its financial guidance for 2025 despite facing one-off costs affecting profitability in the first half of the year [3][6] Revenue Performance - In Q2 2025, Trifork Group's revenue reached EUR 55.1 million, reflecting a 5.1% increase from Q2 2024, with organic growth of 2.9% and inorganic growth of 2.2% [5] - The product-based segment, Run, saw a significant revenue increase of 51.6% to EUR 19.3 million, contributing 33.6% to total revenue [1][5] Public Sector Growth - The public sector business experienced a robust growth of 19.1% in the first half of 2025, now accounting for 39.7% of total revenue [2] - Trifork won 11 out of 13 tenders during this period, indicating a strong competitive position [2] Profitability and Costs - Profitability in the first half of 2025 was impacted by one-off costs related to rightsizing initiatives and pre-sales efforts, with benefits expected to materialize in the second half [3] - Adjusted EBITDA for Q2 2025 was EUR 5.2 million, with a margin of 9.4%, down from 11.0% in Q2 2024 [5] Segment Performance - The Inspire segment's revenue declined by 40.1% to EUR 1.4 million, while the Build segment's revenue decreased by 7.8% to EUR 34.3 million [5] - Adjusted EBITDA margin for the Build segment was 9.1%, down from 13.0% in Q2 2024 [5] Financial Outlook - The financial outlook for the full year 2025 remains unchanged, with expected revenue in the range of EUR 215-225 million, indicating total growth of 4.4-9.3% [11] - Organic revenue growth is anticipated to be between 2.9-7.8%, with adjusted EBITDA in the Trifork Segment projected to be EUR 32.0-37.0 million [11]